COMBIVIR 150 MG
LAMIVUDINE : 150 MG ZIDOVUDINE : 300 MG · DIN 02239213 · VIIV HEALTHCARE ULC
Health Canada status: CANCELLED POST MARKET
What is COMBIVIR?
COMBIVIR 150 MG contains LAMIVUDINE : 150 MG ZIDOVUDINE : 300 MG. It is listed in the Health Canada Drug Product Database under DIN 02239213, held by VIIV HEALTHCARE ULC, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 31-Dec-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is COMBIVIR used for?
COMBIVIR (lamivudine and zidovudine), in combination with other antiretrovirals, is indicated for the treatment of HIV infection.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
What else is COMBIVIR called?
The same molecule, ZIDOVUDINE AND LAMIVUDINE, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Retrovir | Latin | Australia, Bahrain, Morocco, South Africa, United Arab Emirates |
| Aspen Zidovudine | Latin | South Africa |
| AVIRO-Z | Latin | Morocco |
| Cipla Zidovudine Oral Solution | Latin | South Africa |
| Cipla-Zidovudine | Latin | South Africa |
| ZIDOVIR | Latin | Morocco |
| Adco-Zidovudine Syrup | Latin | South Africa |
| Adco-Zidovudine Tablets | Latin | South Africa |
| Aspen Zidovudine Syrup | Latin | South Africa |
| Cipla Duovir | Latin | South Africa |
| Colamziv | Latin | South Africa |
| Mivirdo | Latin | South Africa |
| Retrovir IV | Latin | South Africa |
| Triplavar | Latin | South Africa |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 02239213 |
|---|---|
| Brand name | COMBIVIR |
| Generic / active ingredient | LAMIVUDINE : 150 MG ZIDOVUDINE : 300 MG |
| Manufacturer | VIIV HEALTHCARE ULC |
| Strength | 150 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | J05AR01 ZIDOVUDINE AND LAMIVUDINE |
| AHFS class | 08:18.08.20 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 31-Dec-2024 |
| Original market date | 1998-12-08 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02239213 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2239213 |
| Brand name | COMBIVIR |
| Active ingredient / INN | LAMIVUDINE : 150 MG ZIDOVUDINE : 300 MG |
| ATC code | J05AR01 |
| ATC anatomical main group | J — Anti-infectives for systemic use |
| ATC therapeutic subgroup | J05 |
| AHFS class | 08:18.08.20 |
| Health Canada schedule | Prescription |
| Biosimilar biologic | No |
| Market authorization holder | VIIV HEALTHCARE ULC |
How is it stored and handled?
null
How is it supplied?
HDPE bottles of 60 tablets.
Which pack is which?
| Strength on the label | 150 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Packaging as described in the monograph | HDPE bottles of 60 tablets. |
| Storage | null |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
What can be used instead?
Other Canadian products sharing ATC code J05AR01 ZIDOVUDINE AND LAMIVUDINE. 3 of 5 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-LAMIVUDINE-ZIDOVUDINE | 300 MG | TABLET | APOTEX INC | MARKETED | DIN 02375540 |
| AURO-LAMIVUDINE/ZIDOVUDINE | 150 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02414414 |
| JAMP LAMIVUDINE / ZIDOVUDINE | 300 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02502801 |
| TEVA-LAMIVUDINE/ZIDOVUDINE | 150 MG | TABLET | TEVA CANADA LIMITED | CANCELLED POST MARKET | DIN 02387247 |
Who else supplies ZIDOVUDINE AND LAMIVUDINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. ZIDOVUDINE AND LAMIVUDINE appears in 1364 registered pack listings across 10 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does ZIDOVUDINE AND LAMIVUDINE cost around the world?
ZIDOVUDINE AND LAMIVUDINE is listed on 8 national price registers Nexara tracks, across 49 pack listings published on 7 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| South Africa | single exit price | 24 | 30 | 01 Sep 2026 |
| Morocco | PPV (public price) | 3 | 6 | 05 Sep 2026 |
| Australia | ex-manufacturer | 1 | 3 | 08 Sep 2026 |
| Greece | producer price (ex-factory) | 3 | 3 | 03 Sep 2026 |
| United Arab Emirates | public | 1 | 2 | 31 Aug 2026 |
| Saudi Arabia | public | 2 | 2 | 01 Sep 2026 |
| United States | acquisition | 2 | 2 | 03 Sep 2026 |
| Bahrain | retail (max) | 1 | 1 | 01 Sep 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.